Edwards Lifesciences Climbs 0.41% on $260M Volume Despite 385th Market Rank as Analysts Back Buys and EPS Growth Amid Institutional Bullishness and Insider Selling

Edwards Lifesciences (EW) rose 0.41% on August 28, 2025, with a trading volume of $260 million, ranking 385th in market activity. Analysts highlighted strategic growth opportunities, including proactive investments in the asymptomatic TAVR market ahead of a potential CMS reimbursement decision by late 2025. William Blair analyst Brandon Vazquez reiterated a Buy rating, citing the company’s focus on margin expansion and double-digit EPS growth. RBC Capital also maintained a Buy rating with a $89 price target, though insider sentiment remained negative due to increased share sales by corporate insiders.

Recent institutional activity showed mixed trends. MetLife Investment Management reduced its stake by 2.1%, while Jennison Associates and Northern Trust increased holdings, collectively owning 79.46% of shares. Quarterly earnings exceeded expectations, with revenue rising 11.9% year-over-year to $1.53 billion. Despite strong fundamentals, technical indicators remained bearish, including Hanging Man and Marubozu patterns, signaling potential trend exhaustion. Analysts noted reduced market pressure following Boston Scientific’s exit from heart-valve competition, though caution persisted over technical weaknesses.

Query limit exceeded.